Engineering Enzymes with Potential Against ALS and Parkinson's Disease

Why It Matters

By dramatically speeding up the discovery of potent disaggregases, the work could shorten the path to disease‑modifying treatments for ALS and Parkinson’s, conditions with limited therapeutic options.

Key Takeaways

• Developed high‑throughput method to screen millions of Hsp104 variants
• Engineered Hsp104 variants can disaggregate TDP‑43 and α‑synuclein aggregates
• Deep sequencing enables simultaneous assessment of enzyme efficacy across library
• Approach accelerates discovery of therapeutic disaggregases for ALS and Parkinson’s
• Study published in Molecular Cell; lead author now at Bayer

Pulse Analysis

Protein aggregation lies at the heart of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. Misfolded proteins like TDP‑43 and α‑synuclein form toxic inclusions that disrupt neuronal function, and despite intense research, few therapies can effectively clear these aggregates. Traditional approaches to engineer disaggregase enzymes have been hampered by slow, low‑throughput screening, limiting the ability to explore the vast mutational space needed for optimal activity.

The WashU team’s breakthrough combines yeast‑based expression with a massive mutagenesis library and next‑generation deep sequencing. By introducing tens of millions of mutations into the yeast Hsp104 gene, each colony produces a distinct enzyme variant. High‑throughput colony picking, followed by pooled sequencing, lets researchers assess the entire library in a single run, rapidly identifying mutants that selectively dissolve TDP‑43 or α‑synuclein while minimizing off‑target effects. This platform cuts screening time from months to days and expands the searchable sequence space by orders of magnitude, delivering a pipeline that can be adapted to other aggregation‑prone proteins.

For the biotech sector, the method offers a scalable route to generate therapeutic candidates that target the root cause of protein‑misfolding diseases. Pharmaceutical firms have long pursued small‑molecule chaperones with limited success; engineered disaggregases present a biologic alternative with the potential for higher specificity. While clinical translation will require extensive validation, the rapid‑screening framework accelerates pre‑clinical discovery, attracting investment and collaborations. As the pipeline matures, it could reshape the therapeutic landscape for ALS, Parkinson’s, and related neurodegenerative conditions, delivering hope to patients and new avenues for drug developers.